Six Year Outcome of Selective Laser Trabeculoplasty Trial (LiGHT Trial)

Six Year Outcome of Selective Laser Trabeculoplasty Trial (LiGHT Trial)

We have previously discussed selective laser trabeculoplasty as a treatment option for glaucoma.  Selective laser trabeculoplasty is a non-invasive, painless and quick treatment to help lower eye pressure by improving drainage through the natural drainage channels (trabecular meshwork).

The LiGHT study originally showed that selective laser trabeculoplasty was as effective as eye drops in the initial management of glaucoma or ocular hypertension. This has resulted in a change in the NICE guidelines, where selective laser trabeculoplasty is recommended as a first-line treatment for glaucoma in suitable patients.

Just recently the 6-year outcomes of the LiGHT study were published, which showed that selective laser trabeculoplasty was more effective at maintaining eye pressure control and superior to glaucoma drops in preventing the progression of glaucoma.

One important aspect of the study was looking at the quality of life of patients through patient-reported outcome measures.  Patients who were treated with selective laser trabeculoplasty, not surprisingly, had more comfortable eyes than those on glaucoma drops.

The results are very encouraging that even 6 years down the line, selective laser trabeculoplasty, which can be repeated when needed, offers an excellent long-term alternative to glaucoma patients instead of long-term eye drops, which have the drawback of side effects such as redness and soreness as well as the inconvenience of having to put the drops in. 

At Innovation Eye Clinic we will always discuss all treatment options for your glaucoma and work out an individualised treatment plan for you.

I hope you found this blog useful and if so please do share it with friends and family.

For more information please visit our website: or contact us at or 0800 005 3335.